Lighthouse Pharmaceuticals Secures $49.2 Million NIH Grant for Novel Alzheimer's Disease Treatment Targeting Bacterial Infection
核心洞察
Lighthouse Pharmaceuticals (搜索) received a $49.2 million grant from the National Institute on Aging to advance Phase 2 trials of LHP588, targeting Porphyromonas gingivalis (搜索) infections in Alzheimer's disease (搜索) patients.
The SPRING trial will evaluate LHP588, an oral lysine-gingipain (搜索) inhibitor, in 300 patients with mild to moderate Alzheimer's disease (搜索) who test positive for P. gingivalis in saliva samples.
Previous clinical studies demonstrated that gingipain inhibitors significantly slowed cognitive decline in P. gingivalis-positive Alzheimer's patients, with bacterial reduction correlating to improved clinical outcomes.
Lighthouse Pharmaceuticals (搜索) announced it has secured a $49.2 million grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to advance Phase 2 clinical trials of LHP588 for Alzheimer's disease (搜索) patients with confirmed Porphyromonas gingivalis (搜索) infections. The funding represents a significant validation of the emerging connection between bacterial infections and Alzheimer's disease progression.
Novel Mechanism Targets Bacterial Driver of Neurodegeneration
LHP588 is an orally administered, brain-penetrant lysine-gingipain (搜索) (Kgp) inhibitor designed to selectively block the activity of this key virulence factor of P. gingivalis, thereby reducing the bacteria's toxicity and viability. P. gingivalis, best known as a keystone pathogen in chronic periodontitis (搜索), has been increasingly implicated in chronic systemic inflammation and cognitive decline.
"We are honored to receive this support from the NIA. It is powerful validation of the growing body of evidence connecting P. gingivalis to Alzheimer's disease (搜索) and the potential of gingipain inhibition as a therapeutic strategy," said Casey Lynch, Chief Executive Officer of Lighthouse Pharma. "We are proud to lead this pioneering trial aimed at modifying the disease process by targeting a known microbial driver of neuroinflammation and neurodegeneration."
Phase 2 SPRING Trial Design
The Phase 2 SPRING (Stopping PRogression of P. gINGivalis-positive Alzheimer's disease (搜索) with gingipain inhibition) trial will evaluate the safety, tolerability, and efficacy of high and low doses of LHP588 compared to placebo in 300 patients with mild to moderate Alzheimer's disease. The randomized, double-blind, placebo-controlled study will specifically enroll patients who test positive for P. gingivalis in saliva samples.
The trial is supported by the NIA under award number R01AG088524 and is registered at clinicaltrials.gov under trial identifier NCT06847321.
Promising Preclinical Evidence
Previous clinical studies of Kgp inhibitors in mild-to-moderate Alzheimer's disease (搜索) patients yielded significant reduced cognitive decline in designated P. gingivalis subgroups, along with reducing P. gingivalis presence in saliva. These results correlated with improved clinical outcomes, providing the scientific foundation for the current Phase 2 investigation.
"This grant enables a rigorous clinical test of a truly novel mechanism of action in Alzheimer's disease (搜索)," said Marwan Sabbagh MD, Chair of Lighthouse Pharma's Clinical Advisory Board. "By directly inhibiting lysine-gingipain (搜索), LHP588 offers a targeted approach to intervening in the infectious and inflammatory cascade that may underlie the disease in P. gingivalis-positive AD patients."
Addressing Critical Unmet Need
Alzheimer's disease (搜索) affects over 6 million Americans and remains without a cure. Emerging evidence suggests that chronic infection with P. gingivalis contributes to the progression of Alzheimer's through the production of gingipains (搜索)—neurotoxic proteases that promote inflammation, neuronal damage, amyloid-beta accumulation, and tau pathology.
This positions LHP588 to provide patients diagnosed with Alzheimer's disease (搜索) and P. gingivalis infections a targeted treatment solution, representing a precision medicine approach to addressing this devastating neurodegenerative condition.